|Articles|April 1, 2018
- Pharmaceutical Executive-04-01-2018
- Volume 38
- Issue 4
Pharmaceutical Executive, April 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 8 years ago
Rewriting Pharma’s Talent Blueprintabout 8 years ago
Trading Big Pharma for Small Startupabout 8 years ago
HEOR Education: Evolving the Skill Setabout 8 years ago
Drug Marketing and Advertising Under Fireabout 8 years ago
A Watchful Eye on AIabout 8 years ago
The New Talent Trajectoryabout 8 years ago
HBA's Woman of the Year 2018about 8 years ago
The New (Augmented) Reality in the Life Sciencesabout 8 years ago
Med Affairs Building Up its Strategic Muscleabout 8 years ago
The Top Barriers to Patient PersistenceAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5